Answers are grounded in this paper and cite their sources.
Results in a series of 60 patients with recurrent or metastatic transitional cell carcinoma of the bladder confirm that methotrexate is active as a single agent. Over-all, 43 per cent of the patients with measurable metastases and 28 per cent with recurrent primary tumors responded for an average of 6 months. Response rates in both groups were influenced by the stage of the primary tumor.
No takes yet. Share an insight, caveat, or question.
Oliver et al. (1984) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: